
The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.
VICTORIA (NCT05192642), is an exact-matching study comparing the outcomes of patients with TRK fusion cancer treated with larotrectinib in 3 clinical trials (NCT02122913, NCT02576431, NCT02637687) to patients treated with non-TRK inhibitor therapies in the real-world (RW) setting.





